Association between CTC AR-V7 and overall survival in mCRPC. A total... | Download Scientific Diagram
Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis–Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting - European Urology ...
IJMS | Free Full-Text | The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone
Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study | Journal of Nuclear Medicine
Real World Patterns of PSA Response and Survival with Abiraterone and Enzalutamide in Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Clinical Oncology and Research | Science Repository | Open Access
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry | Prostate Cancer and Prostatic Diseases
Pluvicto Delays Progression in Earlier mCRPC, but Crossover Muddies Overall Survival Analysis | Precision Medicine Online
ASCO GU 2022: Overall Survival after Progression on First Novel Hormonal Therapy in Patients with Metastatic Castration-Sensitive Versus Castration-Resistant Prostate Cancer (mCSPC Versus mCRPC)
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial - ScienceDirect
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases
Frontiers | Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel
Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry | Targeted Oncology
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design -
Overall Survival (OS) for mCRPC patients treated with docetaxel for a... | Download Scientific Diagram
Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study - Nakajima - 2021 - International
Targeted Alpha Therapy Optimising Survival in Advanced Prostate Cancer
Overall survival. mCRPC metastatic castration-resistant protate cancer.... | Download Scientific Diagram
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer | NEJM
A Retrospective Study of the Effect of Metformin on Patients with Metastatic Prostate Cancer - Chung-Shien Lee, So Yi Lam, Angel Liu, Cristina Sison, Xin-Hua Zhu, 2023
Understanding what matters to metastatic castration‐resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey - George - 2023 - Cancer Medicine - Wiley Online Library
Overall survival and second primary malignancies in men with metastatic prostate cancer | PLOS ONE
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
Full article: A registry-based study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide
Medicus Economics, LLC on LinkedIn: Real-world treatment patterns and overall survival among men with…
PROpel Trial Efficacy – LYNPARZA® (olaparib) for BRCAm mCRPC
Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study | In Vivo
Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study | BMC Cancer | Full Text
Efficacy I PLUVICTO
mCRPC: PREVAIL Trial | HCP Site | XTANDI® (enzalutamide)
Optimal sequencing of commonly used medications for treatment of metastatic castration-resistant prostate cancer - Mayo Clinic
